"10.1371_journal.pone.0050397","plos one","2012-11-30T00:00:00Z","Richard Stebbings; Michèle Février; Bo Li; Clarisse Lorin; Marguerite Koutsoukos; Edward Mee; Nicola Rose; Joanna Hall; Mark Page; Neil Almond; Gerald Voss; Frédéric Tangy","Division of Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom; Unité de Génomique Virale et Vaccination, Institut Pasteur, Paris, France; GlaxoSmithKline Vaccines, Rixensart, Belgium; Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom","Conceived and designed the experiments: RS CL MP NA GV FT MK. Performed the experiments: MF BL EM NR JH MP. Analyzed the data: RS BL CL MK GV MP FT. Contributed reagents/materials/analysis tools: RS CL NR MP NA GV FT. Wrote the paper: RS BL CL FT.","CL, MK and GV are employees of GlaxoSmithKline Vaccines. GlaxoSmithKline Biologicals partly funded this study. RS, MF, BL, EM, NR, JH MP and NA declare no competing interest. FT and CL are listed as Inventor of patents related to the measles vector vaccine, the rights of which have been assigned to the Institut Pasteur. Both authors do not hold a patent for the measles vector vaccine described in the present study. MK and GV own shares and/or options to shares in GSK. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","11","Richard Stebbings","RS",12,FALSE,7,6,7,4,TRUE,TRUE,FALSE,0,NA,FALSE
